



# Q1 2024 Financial Results

# Appendix

# Anylam Pharmaceuticals, Inc.

## Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands, except per share amounts)

	Three Months Ended	
	March 31, 2024	March 31, 2023
<b>Reconciliation of GAAP to Non-GAAP Research and development:</b>		
GAAP Research and development	\$ 260,995	\$ 230,569
Less: Stock-based compensation expenses	(19,215)	(16,232)
Non-GAAP Research and development	<u>\$ 241,780</u>	<u>\$ 214,337</u>
<b>Reconciliation of GAAP to Non-GAAP Selling, general and administrative:</b>		
GAAP Selling, general and administrative	\$ 210,797	\$ 183,659
Less: Stock-based compensation expenses	(26,132)	(23,715)
Non-GAAP Selling, general and administrative	<u>\$ 184,665</u>	<u>\$ 159,944</u>
<b>Reconciliation of GAAP to Non-GAAP Operating gain (loss):</b>		
GAAP Operating loss	\$ (43,435)	\$ (149,807)
Add: Stock-based compensation expenses	45,347	39,947
Non-GAAP Operating gain (loss)	<u>\$ 1,912</u>	<u>\$ (109,860)</u>



# Anylam Pharmaceuticals, Inc.

## Reconciliation of Revenue and Growth at Constant Currency

	Three Months Ended March 31, 2024
Total TTR net product revenue growth, as reported	29 %
Add: Impact of foreign currency translation	1
Total TTR net product revenue growth at constant currency	<u>30 %</u>
Total Rare net product revenue growth, as reported	40 %
Add: Impact of foreign currency translation	(1)
Total Rare net product revenue growth at constant currency	<u>39 %</u>
Total net product revenue growth, as reported	32 %
Add: Impact of foreign currency translation	—
Total net product revenue growth at constant currency	<u>32 %</u>
Total revenue growth, as reported	55 %
Add: Impact of foreign currency translation	—
Total revenue growth at constant currency	<u>55 %</u>